Cita APA

Harrington, K., Kitano, S., Gambardella, V., Parkes, E., Moreno, I., Alonso, G., . . . Lorusso, P. (2025). Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.

Citación estilo Chicago

Harrington, K., et al. Open-label, Phase Ia Study of STING Agonist BI 1703880 Plus Ezabenlimab for Patients With Advanced Solid Tumors. 2025.

Cita MLA

Harrington, K., et al. Open-label, Phase Ia Study of STING Agonist BI 1703880 Plus Ezabenlimab for Patients With Advanced Solid Tumors. 2025.